Agios to Webcast Conference Call of Third Quarter 2024 Financial Results on October 31, 2024
Agios Pharmaceuticals Initiated at Sector Outperform by Scotiabank
Agios Pharmaceuticals Price Target Announced at $51.00/Share by Scotiabank
Leerink Partners Maintains Agios Pharmaceuticals(AGIO.US) With Hold Rating
4 Analysts Have This To Say About Agios Pharmaceuticals
Raymond James Upgrades Agios Pharmaceuticals(AGIO.US) to Buy Rating, Announces Target Price $51
Raymond James Reinstates Outperform on Agios Pharmaceuticals, Announces $51 Price Target
Leerink Partners Maintains Agios Pharmaceuticals(AGIO.US) With Hold Rating, Maintains Target Price $56
Agios Pharmaceuticals Down Over 6%, on Pace for Largest Percent Decrease Since September 2022 -- Data Talk
Agios Pharmaceuticals' Shares Fall After Downgrade From Leerink Partners
Agios Cut at Leerink on Overhang From Pfizer's Oxbryta Withdrawal
This HP Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Friday
Micron To $150? Here Are 10 Top Analyst Forecasts For Friday
Leerink Partners Downgrades Agios Pharmaceuticals(AGIO.US) to Hold Rating, Cuts Target Price to $56
Express News | Agios Pharmaceuticals Inc : Leerink Partners Cuts to Market Perform From Outperform; Cuts Target Price to $56 From $60
BofA Securities Maintains Agios Pharmaceuticals(AGIO.US) With Buy Rating, Raises Target Price to $57
Piper Sandler Maintains Agios Pharmaceuticals(AGIO.US) With Buy Rating, Maintains Target Price $56
Express News | Agios Pharmaceuticals Shares up 5% After Rival Pfizer Withdraws Sickle Cell Disease Treatment
RBC Capital Reiterates Outperform on Agios Pharmaceuticals, Maintains $55 Price Target
Agios Pharmaceuticals Analyst Ratings